Literature DB >> 32496166

Chimeric Antigen Receptor T Cell Immunotherapy: What You Need to Know #393.

Ramy Sedhom, Arjun Gupta, Areej El-Jawahri.   

Abstract

Mesh:

Substances:

Year:  2020        PMID: 32496166      PMCID: PMC7718844          DOI: 10.1089/jpm.2020.0138

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


× No keyword cloud information.
  6 in total

1.  Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

Authors:  E Van Den Neste; N Schmitz; N Mounier; D Gill; D Linch; M Trneny; N Milpied; J Radford; N Ketterer; O Shpilberg; U Dührsen; D Ma; J Brière; C Thieblemont; G Salles; C H Moskowitz; B Glass; C Gisselbrecht
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

Review 3.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2017-09-19       Impact factor: 66.675

4.  Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs.

Authors:  Angela K Green; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2018-03-16       Impact factor: 44.544

Review 5.  The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.

Authors:  Bianca Santomasso; Carlos Bachier; Jason Westin; Katayoun Rezvani; Elizabeth J Shpall
Journal:  Am Soc Clin Oncol Educ Book       Date:  2019-05-17

Review 6.  Chimeric antigen receptor T-cell therapies for lymphoma.

Authors:  Jennifer N Brudno; James N Kochenderfer
Journal:  Nat Rev Clin Oncol       Date:  2017-08-31       Impact factor: 66.675

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.